Instituto Gulbenkian de Ciência, Oeiras, Portugal - 19-22 September, 2017
http://gtpb.igc.gulbenkian.pt/bicourses/2017/IO17/index.html
The immuno-oncology approach leverages on the unique capability of the immune system to recognize and kill tumour cells. This action is hampered by escape mechanisms put in place by tumour cells like, for instance, the engagement immune checkpoints, i.e. inhibitory molecules that modulate the amplitude and duration of immune responses. Immunotherapies that block checkpoint molecules are amongst the most promising approaches in immuno-oncology for the enhancement of antitumour immunity. Thanks to high-throughput technologies, such as next-generation sequencing (NGS) and proteomics, we have now access to large-scale tumour data that can be used to investigate the interplay between tumour and immune cells and the role of the immune system in tumour progression and response to therapy. In this course, you will learn to use bioinformatics tools and mathematical modelling techniques operating on high-throughput tumour data, in order to extract features that can be used to characterise this complex tumour-immune cell interface, such as:
- Tumour antigens recognized by T cells
- Tumour-infiltrating immune cells
- Deregulated signalling pathways in cancer and immune cells
A fully practical, hands-on approach will ensure that the newly acquire skills can be used with a great deal of autonomy.
Motivated researchers, clinicians, and students who want to gain an understanding on how bioinformatics tools and simple (logic-based) modelling approaches can be used to investigate the tumour-immune cell interface and its underlying signalling pathways from high-throughput data.
Programming/scripting skills are helpful, but not mandatory. An understanding of elementary operations with R will be required. Elementary command line instructions in UNIX will be used, so minimal familiarity with navigation in directory trees, copying files and folders, etc. will be needed.
A detailed program is reported here.